Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ronald George (NPI 1265657894)

Field	Value
Entity Type	Individual
Organization	Ronald George
Address	2421 Silver Stream Ln
City	Wilmington
State	NC
ZIP	28401
Taxonomy	Rheumatology Physician
NPI Enumerated	April 17, 2007

Payer Source	Total Paid
Medicare	$2.5M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused rheumatology practice: lifetime Medicare revenue is $2.5M while there is no Medicaid billing on file, indicating a single-payer footprint in the available data and limited or no engagement with Medicaid populations. That concentration suggests the practice’s patient mix and reimbursement exposure are overwhelmingly Medicare-driven.

Revenue is highly concentrated in a small set of drugs and infusions: the precomputed share shows the top 3 Medicare codes by revenue account for 66.2% of total Medicare revenue. The leading single code is J0129 (abatacept) with $681.7K (26.4% of Medicare revenue), followed closely by J3262 (tocilizumab) with $661K (25.6%), and J1602 (golimumab IV) with $366.8K (14.2%), indicating biologic infusion services are the core revenue drivers.

The code mix and top services point to an infusion-centered rheumatology operation: high-revenue injectable biologics J0129, J3262, and J1602 plus frequent use of infusion administration codes such as 96365 and 96366 indicate the practice administers intravenous and complex subcutaneous therapies on-site rather than primarily managing patients with office-only visits. The presence of multiple infusion-related codes and high-volume drug administration supports a service line organized around in-clinic biologic therapy.

Competitive standing for key drugs is mixed: the provider ranks in the 96th percentile nationally for J3262 (notably above typical national volume) and ranks #2 of 25 nationally for biosimilar Q5121 (96th percentile), signaling unusually high national activity for tocilizumab and one infliximab biosimilar relative to peers. By contrast, other high-revenue biologics such as J0129 and J1602 appear in more typical national volume bands (89th and 88th percentiles respectively), indicating leadership in a subset of biologic administrations but otherwise typical specialist volumes.

Several procedural and drug codes are statistical outliers in volume relative to peers, which points to an operational emphasis on infusion throughput: 96365 (initial IV infusion) ranks in the 99th percentile and is labeled an extreme outlier (far above typical national volume), while J3489 (zoledronic acid) is described as an extreme outlier at the 100th percentile and J1720 (hydrocortisone sodium succinate) ranks at the 99th percentile. These outlier signals reinforce that the practice delivers a heavy volume of administered therapies and infusion-related procedures.

Office E/M activity is present but not the primary revenue source: 99214 generated $85.6K (3.3% of Medicare revenue) and the provider ranks in the 98th percentile for this established-patient office visit code, showing a high volume of moderate-complexity outpatient visits consistent with ongoing rheumatology management alongside infusion services. New-patient E/M codes (e.g., 99205 and 99204) appear at much lower volumes, suggesting the practice’s workflow is weighted toward established patient care.

Tenure in the Medicare program is long-standing: the NPI was enumerated on 2007-04-17 (~19 years ago), indicating sustained participation in Medicare and likely an established referral and treatment pattern for rheumatologic biologic therapies over nearly two decades. That long tenure aligns with the developed infusion service lines and high-volume administration codes.

The absence of any Medicaid claims means this provider will be a single-payer consideration for networks and analyses that emphasize Medicaid access; any competitive evaluation or contracting discussion that relies on Medicaid volumes should treat this provider as not contributing to Medicaid capacity. For Medicare-focused network design or specialty infusion capacity planning, however, the practice represents a concentrated source of biologic administration.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

47 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	20,050	$30	$681.7K
J3262	Injection, tocilizumab, 1 mg	132,210	$10	$661K
J1602	Injection, golimumab, 1 mg, for intravenous use	33,350	$10	$366.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	8,350	$30	$217K
J9312	Injection, rituximab, 10 mg	2,550	$60	$163.2K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	24,000	$1	$96K
J0897	Injection, denosumab, 1 mg	4,860	$20	$87.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	980	$90	$85.6K
Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	3,120	$20	$65.5K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	1,340	$40	$58.7K

Showing 1–10 of 47

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 47 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Ronald George — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

47 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	11	70	9,530	$30	$393.2K
J3262	2	40	37,160	$1	$224.8K
J0717	26	40	37,400	$1	$178.8K
J9312	8	20	2,070	$60	$178.1K
J1602	8	70	11,900	$10	$175.9K
J1745	7	80	4,110	$30	$117.3K
J0897	87	430	2,100	$20	$63.9K
Q5121	1	10	1,160	$20	$32.2K
J1439	14	30	16,500	$1	$23.1K
83970	155	300	50	$40	$23K

Showing 1–10 of 47

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ronald George, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Wilmington Health PLLC	NC	Pediatrics Physician	$0	$10M
Medical Foundation, Inc.	MS	Geriatric Medicine (Family Medicine) Physician	$0	$1.8M
Alireza Namini	CA	Neuroradiology Physician	$725.7K	$90
Nila Alsheik	IL	Diagnostic Radiology Physician	$332.8K	$300.3K
Michael Marte	SC	Hematology & Oncology Physician	$607.8K	$0
Damian Brezinski	NC	Interventional Cardiology Physician	$506.3K	$30.7K
John D'souza	OH	Diagnostic Radiology Physician	$470.9K	$0
Johny Ardeljan	NC	Neurology Physician	$445.7K	$0
Nzeadibenma Uzochukwu	IL	Diagnostic Radiology Physician	$84K	$360.8K
Adam Braithwaite	NC	Diagnostic Radiology Physician	$435.2K	$0

Nearby Providers

Other providers in the same ZIP code as Ronald George, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Novant Health New Hanover Regional Medical Center LLC	NC	General Acute Care Hospital	$0	$57.5M
New Hanover Regional Medical Center	NC	General Acute Care Hospital	$0	$23.7M
Access Family Services	NC	Community/Behavioral Health Agency	$0	$15.3M
Care Providers Of Wilmington	NC	Home Health Agency	$0	$10M
Ecep Ii PA	NC	Emergency Medicine Physician	$0	$9.7M
Novant Health New Hanover Regional Medical Center LLC	NC	Ambulance	$6.1M	$2.7M
Coastal Horizons Center Inc.	NC	Community/Behavioral Health Agency	$0	$8.7M
New Hanover Community Health Center Incorporated	NC	Federally Qualified Health Center (FQHC)	$0	$8.5M
Kidzcare Pediatrics, PC	NC	Pediatrics Physician	$0	$8.2M
Rha Health Services, Inc	NC	Community/Behavioral Health Agency	$0	$7.5M

Ronald George — Billing Profile & Reimbursement Data

Sign up for Ronald George — Billing Profile & Reimbursement Data policy alerts

Ronald George — Billing Profile & Reimbursement Data

Sign up for Ronald George — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References